A single infusion of zoledronic acid is more effective at increasing bone mineral density than daily risedronate in men on glucocorticoid therapy, Australian research finds.
A 5mg zoledronic acid infusion increased BMD at the lumbar spine by 4.7% after 12 months in men on glucocorticoid therapy for more than three months, compared with 3.3% in those given 5mg of oral risedronate daily, a study of 265 men found.
BMD at total hip increased by 1.8% in patients given zoledronic acid compared with 0.2% in those treated with risedronate, according to the study by Professor Philip Sambrook and colleagues.
And in men on glucocortcoid therapy for less than three months at baseline, zoledronic acid also increased BMD at the lumbar spine and at the...
This site is intended for Registered Medical Practitioners.
To make the most of Endocrinology Update, you need to be logged in.